As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Avelumab for the treatment of advanced or metastatic urothelial carcinoma.
This review discusses PD-L1 inhibition, pharmacological properties, mechanism of action and major studies featuring Avelumab. It also provides commentary and recommendations from Dr Megan Crumbaker, a medical oncologist specialising in genitourinary cancers at the Kinghorn Cancer Centre, St Vincent’s Sydney.
Please login below to download this issue (PDF)